Regístrese
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Hiperaldosteronismo primario
Información de la revista
Vol. 51. Núm. 5.
Páginas 295-302 (Mayo 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 51. Núm. 5.
Páginas 295-302 (Mayo 2004)
DOI: 10.1016/S1575-0922(04)74619-7
Acceso a texto completo
Hiperaldosteronismo primario
Primary hyperaldosteronism
Visitas
18791
L.A. cuéllar
Autor para correspondencia
cuellarolmedo@yahoo.es

Correspondencia: Dr. L.A. Cuéllar. Sección de Endocrinología y Nutrición. Hospital Universitario del Río Hortega. Cardenal Torquemada, s/n. 47010 Valladolid. España.
, D.A. De Luis, C. terroba
Hospital Universitario del Río Hortega. Instituto de Endocrinología y Nutrición. Valladolid. España
Este artículo ha recibido
18791
Visitas
Información del artículo

El hiperaldosteronismo primario es la causa principal de hipertensión secundaria. Su presentación inicial ha cambiado y presenta normopotasemia como expresión de formas hormonales más leves (hiperplasia adrenal idiopática bilateral).

Presentamos un caso de hiperaldosteronismo primario en un hombre de 71 años de edad, sin hipertensión, que presentó debilidad muscular y una concentración de potasio plasmático de 2,6 mEq/l.

El diagnóstico requiere ser confirmado mediante una sobrecarga salina o una prueba con fludrocortisona. La caracterización de los subtipos se realiza con pruebas de imagen y una prueba postural, valoradas conjuntamente.

La espironolactona es la base del tratamiento médico cuando la intervención quirúrgica no está indicada o cuando el paciente la rechaza. Próximamente, el tratamiento del hiperaldosteronismo primario puede modificarse con un nuevo antagonista selectivo de los receptores de la aldosterona, la eplerenona.

Palabras clave:
Hipopotasemia
Aldosterona
Hiperaldosteronismo

Primary hyperaldosteronism is the primary cause of secondary hypertension. Its initial presentation has changed so that is usually manifests with normokalemia as reflection of a milder hormonal forms of the disease (idiopathic bilateral adrenal hyperplasia).

We report a case of primary hyperaldosteronism in a 71-yearold man without hypertension who presented with muscular weakness. The kalemia was 2.6 mEq/l.

The diagnosis requires confirmation by a salt loading or fludrocortisone test. Characterization of subtypes is achieved by joint assessment of imaging and postural stimulation tests.

Spironolactone is still the basis of medical treatment when surgery is not indicated or is refused by the patient. In the near future, the treatment of primary hyperaldosteronism may be modified by a new selective aldosterone receptor antagonist, eplerenone.

Key words:
Hypokalemia
Aldosterone
Hyperaldosteronism
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.W. Conn.
Presidential address. Part I painting background: part II primary aldosteronism, a new clinical syndrome.
J Lab Clin Med, 45 (1995), pp. 3
[2.]
N.M. Kaplan.
Cautins over the current epidemic of primary aldosteronism.
[3.]
A. Ganguly.
Primary aldosteronism.
N Engl J Med, 339 (1998), pp. 1828-1834
[4.]
M. Stowasser.
Primary aldosteronim: revival of a syndrome [editorial].
J Hypertens, 19 (2001), pp. 363-366
[5.]
R.D. Gordon.
Mineralcorticoid hypertension.
Lancet, 23 (1994), pp. 240-243
[6.]
R.W. Edwards Cristopher.
Primary mineralocorticoid excess syndromes.
Endocrinology 4th ed, pp. 1820-1844
[7.]
M. Matsunaga, A. Hara, T.S. Song, M. Hashimoto, S. Tamori, K. Ogawa, et al.
Asyntomatic normotensive primary aldosteronism. Case report.
Hypertension, 5 (1983), pp. 240-243
[8.]
C.E. Fardella, L. Mosso, C.E. Gómez Sánchez, P. Cortes, J. Soto, L. Gómez, et al.
Primary hyperldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.
J Clin Endocrinol Metab, 85 (2000), pp. 1863-1867
[9.]
R.D. Gordon.
Primary aldosteronism (views).
J Endocrinol Invest, 18 (1995), pp. 495-511
[10.]
P.O. Lim, W.F. Young, T.M. McDonald.
A review of the medical treatment of primary aldosteronism.
J Hyperts, 19 (2001), pp. 353-361
[11.]
M.H. Weinberger, N.S. Fineberg.
The diagnosis of primary aldosteronism and separation of two major subtypes.
Arch Intern Med, 153 (1993), pp. 2125-2130
[12.]
D. Hirohara, K. Nomura, T. Kamoto, M. Ujihara, K. Takano.
Performance of the basal aldosterone to renin action and the of renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives.
J Clin Endocrinol Metab, 86 (2001), pp. 4292-4298
[13.]
W.F. Young, N.M. Kaplan, B.D. Roese.
Approach to the patient with hypertension and hypokalemia.
Up To Date [revista electrónica], 9 (2001),
[14.]
A. Ganguly.
Prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis.
J Clin Endocrinol Metab, 86 (2001), pp. 4002-4003
[15.]
J.r. Young WF.
Minireview: primary aldosteronism. Changing concepts in diagnosis and treatment.
Endocrinology, 144 (2003), pp. 2208-2213
[16.]
A.J. Pérez Pérez.
Hiperaldosteronismo primario: subtipos y diagnóstico de localización [editorial].
Hipertensión, 18 (2001), pp. 257-262
[17.]
J.B. Ferriss, D.G. Beevers, J.J. Brown, D.L. Davies, R. Fraser, A.F. Lever, et al.
Clinical, biochemical and pathological features of low-renin (“primary”) hyperaldosteronism.
Am Heart J, 95 (1978), pp. 375-388
[18.]
S. Abdelhamid, H. Müller-Lobeck, S. Pahl, K. Remberger, J.A. Bönhof, D. Walb, et al.
Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients.
Arch Intern Med, 56 (1996), pp. 1190-1195
[19.]
I. Irony, C.E. Kater, E.G. Biglieri, C.H.L. Shackelton.
Correctable subsets of primary aldosteronism: primary adrenal hyperplasia and renin responsive adenoma.
Am J Hypertens, 3 (1990), pp. 576-582
[20.]
T.J. Tunny, R.D. Gordon, S.A. Klem, D. Cohn.
Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin.
Clin Endocr, 34 (1991), pp. 363-369
[21.]
E. Lurbe, F.J. Chaves, I. Torró, M.E. Armengod, V. Álvarez, J. Redón.
Hiperaldosteronismo remediable con glucocorticoides: diagnóstico genético.
Med Clin (Barc), 113 (1999), pp. 579-582
[22.]
R.G. Dluhy, R.P. Lifton.
Glucocorticoid-remediable aldosteronism.
Endocrinol Metab Clin North Am, 23 (1994), pp. 285-297
[23.]
W.R. Lichfield, B.F. Anderson, R.J. Weiss, R.P. Lifton, R.G. Dluhy.
Intracranial aneurysm and hemorragic stroke in glucocorticoidremediable aldosteronism.
Hypertension, 31 (1998), pp. 445-450
[24.]
D.J. Torpy, R.D. Gordon, J.P. Lin, P.R. Huggard, S.E. Taymans, M. Stowasser, et al.
Familial hyperaldosteronism type II: description a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene.
J Clin Endocrinol Metab, 83 (1998), pp. 3214-3218
[25.]
J.D. Blumenfeld, J.E. Sealey, Y. Schlussel, E.D. Vaughan Jr, T.A. Sos, S.A. Atlas, et al.
Diagnosis and treatment of primary aldosteronism.
Ann Intern Med, 121 (1994), pp. 877-885
[26.]
S.B. Magill, H. Raff, J.L. Shaker, R.C. Brickner, T.E. Knechtges, M.E. Kehoe, et al.
Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism.
J Clin Endocrinol Metab, 86 (2001), pp. 1066-1071
[27.]
F.A. McAlister, R.Z. Lewanczuk.
Primary hyperaldosteronism and adrenal incidentaloma: an argument for physiologic testing before adrenalectomy.
Can J Surg, 41 (1998), pp. 299-305
[28.]
R.G. Fontes, C.E. Kater, E.G. Biglieri, I. Irony.
Reassessment of the predictive value of the postural stimulation test in primary aldosteronism.
Am J Hypertens, 4 (1991), pp. 786-791
[29.]
K. Nomura, K. Kusakabe, M. Maki, Y. Ito, M. Aiba, H. Demura.
Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-supression scintigraphy: relationship to adenoma size and funcional activity.
J Clin Endocrinol Metab, 71 (1990), pp. 825-830
[30.]
J.L. Doppman, J.R. Gill.
Hyperaldosteronism: sampling the adrenal veins (how I do it).
Radiology, 198 (1996), pp. 309-312
[31.]
G.P. Rossi, A. Sachetto, M. Chiesura-Corona, R. De Toni, M. Gallina, G.P. Feltrin, et al.
Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases.
J Clin Endocrinol Metab, 86 (2001), pp. 1083-1090
[32.]
R. Harper, C.G. Ferret, J.A. McKnight, E.M. Mcllrath, C.F. Russell, B. Sheridan, et al.
Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas.
QJM, 92 (1999), pp. 643-650
[33.]
R. Rocha, J.W. Funder.
The pathophysiology of aldosterone in the cardiovascular system.
Ann NY Acad Sci, 970 (2002), pp. 89-100
[34.]
J.r. Stier CT, P.N. Chander, R. Rocha.
Aldosterone as a mediator in cardiovascular injury.
Cardiol Rev, 10 (2002), pp. 97-107
[35.]
C.G. Brilla, R. Pick, L.B. Tan, J.S. Janicki, K.T. Weber.
Remodeling of the rat right and left ventricles in experimental hypertension.
Circ Res, 67 (1990), pp. 1355-1364
[36.]
B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Pérez, et al.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
N Engl J Med, 341 (1999), pp. 709-717
[37.]
N.J. Brown, M.A. Agirbasli, G.H. Willians, W.R. Litchfield, D.E. Vaughan.
Effect of activation and inhibition of the renin angiotensin system on plasma PAI 1.
Hypertension, 32 (1998), pp. 965-971
[38.]
P. Meria, B.F. Kempf, J.F. Heermieu, P.F. Plouin, J.M. Duclos.
Laparoscopic management of primary aldosteronism: clinical experience with 212 cases.
[39.]
A.M. Sawka, W.F. Young Jr, G.B. Thompson, C.S. Grant, D.R. Farley, C. Leibson, et al.
Primary aldosteronism: fators associated with normalization of blod pressure after surgery.
Ann Intern Med, 135 (2001), pp. 258-261
[40.]
Y. Fukudome, K. Fujii, H. Arima, Y. Ohya, T. Tsuchihashi, I. Abe, et al.
Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy.
Hypertens Res, 25 (2002), pp. 11-18
[41.]
P.A. Almeida, F. Costa Alves, P.O. Pinto, M.M. Diniz, G. Pego, L.A. Providencia.
First results in 34 patients with primary aldosteronism treated by CT-guided percutaneous ethanol [resumen].
Am J Hipertens, 14 (2001), pp. 251A
[42.]
X. Jeunemaitre, G. Chatellier, C. Kreft-Jais, A. Charru, C. De Vries, P.F. Plouin, et al.
Efficacy and tolerance of spironolatone in essential hypertension.
Am J Cardiol, 60 (1987), pp. 820-825
[43.]
M. De Gasparo, U. Joss, H.P. Ramjoue, S.E. Whitebread, H. Haenni, L. Schenkel, et al.
Three new epoxy-spironolactone derivates: characterization in vivo and in vitro.
J Pharmacol Exp Ther, 240 (1987), pp. 650-656
[44.]
M. Stowasser, A.W. Bachman, P.R. Huggard, T.R. Rossetti, R.D. Gordon.
Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension.
J Clin Endocrinol Metab, 85 (2000), pp. 3313-3318
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.